Urease-IN-3

Cat. No.: HY-147787: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Urease-IN-3 (Compound L12) is a potent inhibitor of Urease with an IC₅₀ of 1.449 μM. Urease-IN-3 is a flavonoid analogue compound.

For research use only. We do not sell to patients.

Urease-IN-3 Chemical Structure

CAS No. : 2543651-72-3

Size		Stock
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Urease-IN-3 (Compound L12) is a potent inhibitor of Urease with an IC₅₀ of 1.449 μM. Urease-IN-3 is a flavonoid analogue compound^[1].

Molecular Weight

402.37

Formula

C₂₃H₁₅FN₂O₄

CAS No.

2543651-72-3

SMILES

O=C(N/N=C/C1=C(O)C=CC2=C1OC(C3=CC=C(F)C=C3)=CC2=O)C4=CC=CC=C4

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (248.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4853 mL	12.4264 mL	24.8527 mL
5 mM	0.4971 mL	2.4853 mL	4.9705 mL
10 mM	0.2485 mL	1.2426 mL	2.4853 mL

View the Complete Stock Solution Preparation Table

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: 2.5 mg/mL (6.21 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL. If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Liu H, et al. Flavonoid analogues as urease inhibitors: Synthesis, biological evaluation, molecular docking studies and in-silico ADME evaluation. Bioorg Chem. 2020;105:104370. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.4853 mL	12.4264 mL	24.8527 mL	62.1319 mL
	5 mM	0.4971 mL	2.4853 mL	4.9705 mL	12.4264 mL
	10 mM	0.2485 mL	1.2426 mL	2.4853 mL	6.2132 mL
	15 mM	0.1657 mL	0.8284 mL	1.6568 mL	4.1421 mL
	20 mM	0.1243 mL	0.6213 mL	1.2426 mL	3.1066 mL
	25 mM	0.0994 mL	0.4971 mL	0.9941 mL	2.4853 mL
	30 mM	0.0828 mL	0.4142 mL	0.8284 mL	2.0711 mL
	40 mM	0.0621 mL	0.3107 mL	0.6213 mL	1.5533 mL
	50 mM	0.0497 mL	0.2485 mL	0.4971 mL	1.2426 mL
	60 mM	0.0414 mL	0.2071 mL	0.4142 mL	1.0355 mL
	80 mM	0.0311 mL	0.1553 mL	0.3107 mL	0.7766 mL
	100 mM	0.0249 mL	0.1243 mL	0.2485 mL	0.6213 mL

Urease-IN-3 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Urease-IN-32543651-72-3BacterialUreaseflavonoid analogueInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks